Table 4.
The comparison and outcome analyses of the patients with monotherapy of tigecycline or sulbactam
| Variables | TG groupa | SB groupa | p | Deceasedab | Survivorsa | p |
|---|---|---|---|---|---|---|
| n = 39 | n = 13 | n = 11 | n = 41 | |||
| Demographic parameters | ||||||
| Age, yr | 71.4 (15.0) | 68.7 (19.9) | 0.899 | 75.3 (12.0) | 69.5 (17.1) | 0.439 |
| Male gender | 25 (64.1) | 10 (76.9) | 0.506 | 8 (72.7) | 27 (65.9) | 1.000 |
| Concomitant diseases | ||||||
| Hepatic dysfunction | 3 (7.7) | 0 (0.0) | 0.564 | 1 (9.1) | 2 (4.9) | 0.518 |
| Renal insufficiency | 10 (25.6) | 4 (30.8) | 0.729 | 1 (9.1) | 13 (31.7) | 0.251 |
| Chronic pulmonary disease | 11 (28.2) | 4 (30.8) | 1.000 | 4 (36.4) | 11 (26.8) | 0.709 |
| Heart disease | 6 (15.4) | 1 (7.7) | 0.664 | 2 (18.2) | 5 (12.2) | 0.630 |
| Diabetes mellitus | 9 (23.1) | 4 (30.8) | 0.714 | 3 (27.3) | 10 (24.4) | 1.000 |
| Immune compromise | 8 (20.5) | 1 (7.7) | 0.420 | 2 (18.2) | 7 (17.1) | 1.000 |
| Malignancy | 8 (20.5) | 3 (23.1) | 1.000 | 4 (36.4) | 7 (17.1) | 0.216 |
| Surgery | 9 (23.1) | 1 (7.7) | 0.419 | 2 (18.2) | 8 (19.5) | 1.000 |
| Clinical conditions | ||||||
| APACHE II Score | 17.0 (6.1) | 18.2 (6.0) | 0.557 | 17.1 (6.8) | 17.3 (5.9) | 0.904 |
| Ventilator use | 21 (53.8) | 11 (84.6) | 0.048 | 6 (54.5) | 26 (63.4) | 0.730 |
| Bilateral pneumonia | 18 (46.2) | 12 (92.3) | 0.004 | 8 (72.7) | 22 (53.7) | 0.319 |
| Polymicrobial pneumonia | 31 (79.5) | 9 (69.2) | 0.466 | 9 (81.8) | 31 (75.6) | 1.000 |
| With MRSA | 20 (51.3) | 6 (46.2) | 0.749 | 5 (45.5) | 21 (51.2) | 0.734 |
| With Pseudomonas aeruginosa | 14 (35.9) | 3 (23.1) | 0.506 | 5 (45.5) | 12 (29.3) | 0.470 |
| With Klebsiella spp. | 7 (17.9) | 1 (7.7) | 0.662 | 1 (9.1) | 7 (17.1) | 1.000 |
| With Serratia marcescens | 5 (12.8) | 1 (7.7) | 1.000 | 1 (9.1) | 5 (12.2) | 1.000 |
| With Stenotrophomanas maltophilia | 3 (7.7) | 3 (23.1) | 0.157 | 1 (9.1) | 5 (12.2) | 1.000 |
| Multisite infections | 14 (35.9) | 5 (38.5) | 1.000 | 4 (36.4) | 15 (36.6) | 1.000 |
| With urinary tract infection | 7 (17.9) | 3 (23.1) | 0.697 | 2 (18.2) | 8 (19.5) | 1.000 |
| With catheter related infection | 0 (0.0) | 2 (15.4) | 0.059 | 1 (9.1) | 1 (2.4) | 0.382 |
| With skin and soft tissue infection | 3 (7.7) | 1 (7.7) | 1.000 | 1 (9.1) | 3 (7.3) | 1.000 |
| With intra-abdominal infection | 4 (10.3) | 0 (0.0) | 0.561 | 0 (0.0) | 4 (9.8) | 0.567 |
| With invasive fungal infection | 6 (15.4) | 0 (0.0) | 0.317 | 1 (9.1) | 5 (12.2) | 1.000 |
| Microbiology | ||||||
| MDR Acb complex with TG or SB resistancec | 6 (15.4) | 4 (30.8) | 0.244 | 1 (9.1) | 9 (22.0) | 0.668 |
| Airway eradication of MDR Acb complexd | 12 (34.3) | 8 (88.9) | 0.006 | 4 (57.1) | 16 (43.2) | 0.684 |
| Bacteremia during treatment | 2 (5.1) | 0 (0.0) | 1.000 | 1 (9.1) | 1 (2.4) | 0.382 |
| Treatment | ||||||
| Tigecycline-based treatment | 7 (63.6) | 32 (78.0) | 0.435 | |||
| Duration, days | 13.8 (5.1) | 12.7 (5.6) | 0.293 | 11.9 (3.0) | 14.0 (5.6) | 0.398 |
| Delayed treatment | 20 (51.3) | 5 (38.5) | 0.423 | 5 (45.5) | 20 (48.8) | 0.845 |
| Outcomes | ||||||
| Clinical resolution of pneumonia | 26 (66.7) | 8 (61.5) | 0.747 | |||
| Mortality during treatment | 7 (17.9) | 4 (30.8) | 0.435 | |||
| 30-day mortality | 10 (25.6) | 7 (53.8) | 0.089 | |||
Abbreviations: TG tigecycline, SB sulbactam, APACHE acute physiology and chronic health evaluation, MRSA methicillin resistant Staphylococcus aureus, MDR Acb multidrug resistant Acinetobacter calcoaceticus-Acinetobacter baumannii
aCategorical data are no.(%) of subject, continuous data are expressed as mean (standard deviation)
bMortality during treatment
cThe initial airway MDR Acb complex isolates with resistance to TG in TG group, or with resistance to SB in SB group
d35 patients in TG group and 9 in SB group; 7 patients in the deceased group and 37 in the survivors group had available data for evaluation